Exchange: NASDAQ·Updated 03:00 PM EDT
IOVA logo

IOVA Iovance Biotherapeutics Inc

$9.10
$0.495
(5.76%)
Today
EarningsNov 5
Mkt Cap$3.9B
Vol9.43M

About IOVA

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
52

Neutral Sentiment

How do you feel about IOVA?

Advertisement|Remove ads.